| A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection (NCT03980314) | Bristol-Myers Squibb | 2019-06-24 |
| A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer (NCT03873402) | Bristol-Myers Squibb | 2019-06-21 |
| An Ascending Dose Study of BMS-986259 to Study Safety in Healthy Participants (NCT04008992) | Bristol-Myers Squibb | 2019-06-18 |
| A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database (NCT05421442) | Bristol-Myers Squibb | 2019-06-13 |
| A Study to Investigate the Effects of Gastric Acid Suppression by Rabeprazole and BMS-986165 on How Fast and Complete The Drug is Absorbed Into the Body of Healthy Participants (NCT03979248) | Bristol-Myers Squibb | 2019-05-16 |
| A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants (NCT03981094) | Bristol-Myers Squibb | 2019-05-10 |
| A Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of BMS-986205 in Healthy Participants (NCT03936374) | Bristol-Myers Squibb | 2019-05-08 |
| Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male Participants (NCT03939702) | Bristol-Myers Squibb | 2019-05-02 |
| A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of BMS-986256 in Healthy Participants (NCT03950960) | Bristol-Myers Squibb | 2019-05-02 |
| Study to Characterize the Effects of Cytochrome p450 1A2 Inhibition on Systemic Exposure to BMS-986165 (NCT03930602) | Bristol-Myers Squibb | 2019-05-01 |
| An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe Psoriasis (NCT03924427) | Bristol-Myers Squibb | 2019-04-10 |
| An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors (NCT03745807) | Bristol-Myers Squibb | 2019-04-09 |
| Single and Multiple Dose Pharmacokinetics of BMS-986165 in a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Chinese Subjects (NCT03956953) | Bristol-Myers Squibb | 2019-04-04 |
| Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) (NCT03881059) | Bristol-Myers Squibb | 2019-04-01 |
| Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus (NCT03920267) | Bristol-Myers Squibb | 2019-03-26 |
| An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers (NCT03956680) | Bristol-Myers Squibb | 2019-03-26 |
| A Pharmacokinetics, Safety and Tolerability Study of Multiple Formulations of BMS-986231 in Healthy Participants (NCT03891108) | Bristol-Myers Squibb | 2019-02-28 |
| An Investigational Study of BMS-986165 in Participants With Normal Liver Function and Participants With Mild to Severe Liver Damage (NCT03890809) | Bristol-Myers Squibb | 2019-02-26 |
| A Study of Overall Survival in Participants With Metastatic Colorectal Cancer (mCRC) (NCT05420909) | Bristol-Myers Squibb | 2019-01-28 |
| A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel (NCT03766581) | Bristol-Myers Squibb | 2019-01-27 |
| Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy Males (NCT03873415) | Bristol-Myers Squibb | 2019-01-25 |
| An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic (NCT03730961) | Bristol-Myers Squibb | 2019-01-17 |
| Treatment Patterns and Outcomes in Participants With Advanced Melanoma in Germany Using a German Database (NCT05426239) | Bristol-Myers Squibb | 2019-01-09 |
| A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced Melanoma (NCT03696069) | Bristol-Myers Squibb | 2019-01-09 |
| A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies (NCT03834662) | Bristol-Myers Squibb | 2019-01-07 |
| Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis (NCT03831438) | Bristol-Myers Squibb | 2019-01-01 |
| A Study of Treatment Patterns and Clinical Outcomes in First Line Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (1L R/M SCCHN) Participants in Europe (NCT05123950) | Bristol-Myers Squibb | 2019-01-01 |
| A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors (NCT03792750) | Bristol-Myers Squibb | 2018-12-31 |
| An Investigational Study to Evaluate Experimental Medication BMS-986165 Given as a Tablet and Solution in Healthy Male Participants (NCT03739788) | Bristol-Myers Squibb | 2018-12-05 |
| Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in Adults (NCT03208322) | Bristol-Myers Squibb | 2018-11-30 |
| A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different Processes (NCT03714022) | Bristol-Myers Squibb | 2018-11-09 |
| A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer (NCT03661320) | Bristol-Myers Squibb | 2018-11-06 |
| A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) (NCT03668119) | Bristol-Myers Squibb | 2018-10-31 |
| A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) (NCT03656718) | Bristol-Myers Squibb | 2018-10-29 |
| A Study to Assess Overall Survival and Treatment Patterns for Advanced Liver Cancer Participants Who Received Nivolumab Therapy (NCT04161911) | Bristol-Myers Squibb | 2018-10-29 |
| An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers (NCT03662659) | Bristol-Myers Squibb | 2018-10-16 |
| A Taste Assessment of BMS-986165 in Healthy Participants (NCT03751228) | Bristol-Myers Squibb | 2018-10-11 |
| A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects (NCT03698513) | Bristol-Myers Squibb | 2018-10-04 |
| A Study of Participants in Australia Who Have Non-small Cell Lung Cancer Being Treated With Nivolumab (NCT03804554) | Bristol-Myers Squibb | 2018-10-03 |
| A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM (NCT03723655) | Bristol-Myers Squibb | 2018-09-27 |
| Evaluation of Safety and Effectiveness on Oral Anticoagulants (NCT03765242) | Bristol-Myers Squibb | 2018-09-21 |
| A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma (NCT03635983) | Bristol-Myers Squibb | 2018-09-21 |
| A Study to Observe the Onset of Immune-related Adverse Reactions in Patients With Non-surgical or Renal Cell Carcinoma (RCC) That Has Spread (NCT03663946) | Bristol-Myers Squibb | 2018-09-18 |
| An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors (NCT03661632) | Bristol-Myers Squibb | 2018-09-11 |
| An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function (NCT03674476) | Bristol-Myers Squibb | 2018-09-11 |
| An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy Participants (NCT03712540) | Bristol-Myers Squibb | 2018-09-06 |
| An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants (NCT03634969) | Bristol-Myers Squibb | 2018-08-14 |
| An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants (NCT03660436) | Bristol-Myers Squibb | 2018-08-14 |
| An Investigational Study to Evaluate the Effects of Experimental Medication BMS-986256 in Healthy Participants (NCT03634995) | Bristol-Myers Squibb | 2018-08-14 |
| Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis (NCT03624127) | Bristol-Myers Squibb | 2018-08-07 |
| A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder (NCT03519256) | Bristol-Myers Squibb | 2018-08-02 |
| A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US (NCT03732560) | Bristol-Myers Squibb | 2018-07-31 |
| An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis (NCT03611751) | Bristol-Myers Squibb | 2018-07-26 |
| An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease (NCT03599622) | Bristol-Myers Squibb | 2018-07-16 |
| Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection (NCT03487848) | Bristol-Myers Squibb | 2018-06-25 |
| A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis (NCT03486899) | Bristol-Myers Squibb | 2018-06-19 |
| A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis (NCT03486912) | Bristol-Myers Squibb | 2018-06-12 |
| An Investigational Study to Evaluate the Effect of Rifampin on the Singe Dose of Experimental Medication BMS-986224 in Healthy Participants (NCT03563950) | Bristol-Myers Squibb | 2018-06-01 |
| An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread (NCT03459222) | Bristol-Myers Squibb | 2018-05-30 |
| An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram Effects (NCT03541564) | Bristol-Myers Squibb | 2018-05-30 |
| An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function (NCT03515980) | Bristol-Myers Squibb | 2018-05-25 |
| An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer (NCT03417037) | Bristol-Myers Squibb | 2018-05-24 |
| Study of Daclatasvir-based Therapy in Chinese Participants With Chronic Hepatitis C (CHC) (NCT03500562) | Bristol-Myers Squibb | 2018-05-08 |
| An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment (NCT03335540) | Bristol-Myers Squibb | 2018-05-07 |
| Study to Determine if the Flu Vaccine Increases the Risk of Muscle Damage in Participants Taking Drugs That Block Certain Proteins Made by Some Types of Immune System Cells (NCT03644498) | Bristol-Myers Squibb | 2018-05-02 |
| Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER (NCT03496168) | Bristol-Myers Squibb | 2018-04-26 |
| Bioavailability of Apixaban Sprinkle Compared to Apixaban Capsules (NCT03509883) | Bristol-Myers Squibb | 2018-04-26 |
| A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (NCT03383458) | Bristol-Myers Squibb | 2018-04-18 |
| A Study of Abatacept in Participants That Only Recently Started to Develop Rheumatoid Arthritis (NCT03457792) | Bristol-Myers Squibb | 2018-04-17 |
| A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma (NCT03470922) | Bristol-Myers Squibb | 2018-04-11 |
| Study of the Safety of Orencia in Japanese Children and Adolescents With Active Juvenile Arthritis of Unknown Origin (NCT03466814) | Bristol-Myers Squibb | 2018-04-06 |
| An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed (NCT03444753) | Bristol-Myers Squibb | 2018-04-05 |
| An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck (NCT03386838) | Bristol-Myers Squibb | 2018-03-28 |
| A Study of Experimental Medication BMS-986231 in Patients With Different Levels of Kidney Function (NCT03332186) | Bristol-Myers Squibb | 2018-03-15 |
| A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (NCT03048136) | Bristol-Myers Squibb | 2018-03-09 |
| An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread (NCT03446040) | Bristol-Myers Squibb | 2018-03-08 |
| An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants (NCT03419910) | Bristol-Myers Squibb | 2018-03-05 |
| Safety and Effectiveness of Abatacept in Psoriatic Arthritis Participants (NCT03419143) | Bristol-Myers Squibb | 2018-03-02 |
| Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants (NCT02982707) | Bristol-Myers Squibb | 2018-03-01 |
| A Study of Patients Hospitalized With Acute Heart Failure With Reduced Ejection Fraction (HFrEF) (NCT03515655) | Bristol-Myers Squibb | 2018-02-21 |
| An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread (NCT03414983) | Bristol-Myers Squibb | 2018-02-20 |
| A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C (NCT03420768) | Bristol-Myers Squibb | 2018-02-14 |
| A Study of Experimental Medication BMS-986036 Given to Healthy Participants (NCT03445208) | Bristol-Myers Squibb | 2018-02-14 |
| Effectiveness and Safety of Nivolumab in Participants That Have Head and Neck Cancer That Has Come Back or Has Spread (NCT03569436) | Bristol-Myers Squibb | 2018-02-14 |
| Safety and Effectiveness of Nivolumab in Recurring Kidney Cancer Participants (NCT03568435) | Bristol-Myers Squibb | 2018-02-14 |
| A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers (NCT03400332) | Bristol-Myers Squibb | 2018-02-12 |
| v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491 (NCT03447990) | Bristol-Myers Squibb | 2018-02-06 |
| Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort Study (NCT01694693) | Bristol-Myers Squibb | 2018-01-31 |
| An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread (NCT03377361) | Bristol-Myers Squibb | 2018-01-31 |
| Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney Cancer (NCT03455452) | Bristol-Myers Squibb | 2018-01-21 |
| A Real-World Observational Study for the Safety and Efficacy of Baraclude in Korean Pediatric Patients With Chronic Hepatitis B (NCT03426618) | Bristol-Myers Squibb | 2018-01-12 |
| A Study to Investigate BMS-986165 and Methotrexate in Healthy Male Patients (NCT03402087) | Bristol-Myers Squibb | 2018-01-08 |
| The Effectiveness of Nivolumab Monotherapy as First-Line Therapy in Adults With Advanced Melanoma in Germany (NCT03205722) | Bristol-Myers Squibb | 2018-01-05 |
| A Study to Evaluate the Bioavailability of BMS-986205 (NCT03374228) | Bristol-Myers Squibb | 2018-01-04 |
| Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma (NCT02976493) | Bristol-Myers Squibb | 2018-01-01 |
| Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy (NCT03071133) | Bristol-Myers Squibb | 2018-01-01 |
| A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia (NCT03195491) | Bristol-Myers Squibb | 2017-12-25 |
| A Study in Healthy Participants Evaluating the Absorption of a BMS-986205 Tablet Into the Bloodstream Compared to a Reference Tablet (NCT03378310) | Bristol-Myers Squibb | 2017-12-21 |
| An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (NCT03338790) | Bristol-Myers Squibb | 2017-12-19 |
| A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer (NCT03336216) | Bristol-Myers Squibb | 2017-12-18 |